Last reviewed · How we verify

NCT02823093: AVKAL

Aortic Calcification and Vitamin K Antagonists

Status unknown Last updated 30 January 2017
What this trial tests

trial in Vascular Calcification in 338 participants. Status unknown.

Timeline
1 April 2016
Primary endpoint
1 April 2017
1 April 2017

Quick facts

Lead sponsorCentre Hospitalier Universitaire, Amiens
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment338
Start date1 April 2016
Primary completion1 April 2017
Estimated completion1 April 2017
Sites1 location across France

Conditions studied

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

18 and older, any sex, with Vascular Calcification. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The vitamin K antagonists (VKA) are necessary drugs of prevention and treatment of thrombo-embolic disease. The AVKAL study assesses the impact of VKA treatment on the aortic calcifications development. This is a biomedical research without health product, transversal and monocentric study which compares the aortic calcifications levels of two populations : one treated by VKA and the other which has never been treated by VKA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Vascular Calcification

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02823093.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing